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Background: RNA viruses have high mutation rates and exist within their hosts as large, complex and heterogeneous
populations, comprising a spectrum of related but non-identical genome sequences. Next generation sequencing
is revolutionising the study of viral populations by enabling the ultra deep sequencing of their genomes, and the
subsequent identification of the full spectrum of variants within the population. Identification of low frequency
variants is important for our understanding of mutational dynamics, disease progression, immune pressure, and
for the detection of drug resistant or pathogenic mutations. However, the current challenge is to accurately model
the errors in the sequence data and distinguish real viral variants, particularly those that exist at low frequency,
from errors introduced during sequencing and sample processing, which can both be substantial.
Results: We have created a novel set of laboratory control samples that are derived from a plasmid containing a
full-length viral genome with extremely limited diversity in the starting population. One sample was sequenced
without PCR amplification whilst the other samples were subjected to increasing amounts of RT and PCR
amplification prior to ultra-deep sequencing. This enabled the level of error introduced by the RT and PCR
processes to be assessed and minimum frequency thresholds to be set for true viral variant identification. We
developed a genome-scale computational model of the sample processing and NGS calling process to gain a
detailed understanding of the errors at each step, which predicted that RT and PCR errors are more likely to occur
at some genomic sites than others. The model can also be used to investigate whether the number of observed
mutations at a given site of interest is greater than would be expected from processing errors alone in any NGS
data set. After providing basic sample processing information and the site’s coverage and quality scores, the
model utilises the fitted RT-PCR error distributions to simulate the number of mutations that would be observed
from processing errors alone.
Conclusions: These data sets and models provide an effective means of separating true viral mutations from
those erroneously introduced during sample processing and sequencing.
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Figure 1 RNA virus sequencing and error introduction. The typical
steps involved in processing an RNA virus sample for sequencing. At
each step, errors are introduced in the form of artefactual mutations that
will be present in the resultant NGS reads. Artefactual mismatches to the
reference genome are practically indistinguishable from low-frequency
real biological variation within the reads.
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RNA viruses such as foot-and-mouth disease virus (FMDV)
evolve rapidly due to their large population size, high
replication rate and the poor proof-reading ability of their
RNA-dependent RNA polymerase. Mutation rates of RNA
viruses are cited to be between 10−3 and 10−6 mutations
per nucleotide per transcription cycle [1-4], therefore muta-
tions can potentially be introduced every time a viral
genome is replicated. As a result, these viruses exist within
their hosts as large, complex and heterogeneous popula-
tions, comprising a spectrum of related but non-identical
genome sequences [5-8]. The capacity of RNA viruses
to evolve rapidly is a key driver of viral virulence,
vaccine resistance and host-jumping (the infection of a
new species and adaptation to life within the new host).
Therefore, an understanding of the mutational dynam-
ics of RNA viruses is essential for our understanding of
viral disease progression, transmission and the develop-
ment of antiviral therapeutics [9].
Next generation sequencing (NGS) techniques provide
the means for rapid and cost-effective dissection of viral
evolutionary dynamics at an unprecedented level of de-
tail [10-18]. The massively parallel and high-throughput
nature of NGS platforms, combined with the relatively
short genome of an RNA virus, enables the analysis of
viral samples (which can contain billions of virions) to a
very high depth. Such ultra-deep coverage of the genome
enables the diversity of the whole viral population to be
examined and subsequently compared between samples
to investigate evolutionary events such as selection and
bottlenecks. Furthermore, high depth enables the identi-
fication of important variants present within the viral
population at low frequencies, such as those that increase
pathogenicity or convey drug resistance [19] which would
pose a risk if they become dominant in later populations
due to selection. However, a current problem with the ap-
plication of NGS platforms to viral population analysis is
that true low frequency viral variants cannot be effectively
distinguished from variants caused by errors during sam-
ple preparation or sequencing.
Viral samples typically have to undergo substantial
sample processing before sequencing which introduces
errors in the form of artefactual mutations into viral ge-
nomes (Figure 1). This problem is most evident for RNA
viruses that must first be reverse transcribed (RT) to
cDNA, which is then typically amplified by polymerase
chain reaction (PCR) to produce sufficient quantities of
DNA for sequencing on NGS platforms. The RT and
PCR processes are error prone, with the error rate
dependent on the fidelity of the enzymes used. RT is a
non-expansive process, whilst PCR utilises multiple cy-
cles to amplify the DNA in an exponential manner. In
terms of error, the PCR process is cumulative, as any
mutation introduced into a copied viral genome in onecycle will be passed on to all the progeny of that genome
in later cycles in addition to new mutations being intro-
duced. Therefore, there is an increase in the number of
errors introduced into the viral sequences through the
PCR process as the cycle number increases, elevating
the error rate of the PCR process with each cycle.
Focussing on the Illumina platform, after RT and PCR,
viral samples undergo fragmentation via sonication (or
nebulization) to generate DNA fragments of various
sizes. Typically 300-400 bp fragments are then selected
by gel extraction. The process of sonication results in
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via evaporation, and only ~10% of the remaining DNA is
located in the 300-400 bp range [20]. This results in a
total sample loss of ~95% and therefore represents a
sampling bottleneck of 5%. However, the latest Illumina
Nextera DNA sample preparation kit simultaneously
fragments and tags sample DNA with adapters in a
single step (tagmentation) and results in significantly less
sample loss [21] and hence requires substantially less
starting DNA. Illumina library preparation involves the
ligation of Illumina adaptors and unique sequencing tags
onto the ends of DNA fragments followed by 10 cycles
of PCR to amplify the library ready for sequencing on an
Illumina platform.
Base calling on the Illumina platform is complicated
by factors including similar emission spectra of the A/C
and G/T fluorophores as well as phasing and pre-
phasing issues [22]. In terms of error rate, the Illumina
platform is considered to be better than its rivals [23-25]
and every sequenced base in every read is assigned a
quality score that is a measure of the uncertainty of the
base call using the Phred scale. At one of the highest
quality scores Q40, there is a 1 in 10,000 probability of a
base being called incorrectly. Although this is a very low
probability, the ultra-deep coverage of viral samples can
result in a coverage of 10 K-100 K at each position in
the genome. This implies that even if every base were of
the highest quality, we would still expect errors to be in-
troduced via base miscalls from the Illumina machine.
Furthermore, it has been reported that Illumina ma-
chines have a sequence specific error profile whereby
errors occur more frequently around certain motifs such
as GGC and GGX [26-28]. Such systematic errors are
poorly understood given that motifs such as GGC (the
codon for glycine) occur very frequently in DNA, and
yet it is only a small number of these motifs in a genome
that suffer such errors, suggesting that there are other
issues involved such as the DNA sequence further up-
stream of the motif.
The introduction of erroneous mutations during the sam-
ple preparation process and miscalls during base calling
confounds the identification of true low frequency viral var-
iants. Consequently, true low-frequency variants will be
practically indistinguishable from process error, whilst high
frequency viral variants will be easily identified, as they are
observable at levels much higher than can be attributed to
error. However, there have been few experimental analyses
to determine thresholds above which a variant is highly
likely to be real. Furthermore, there are very few computa-
tional methods available to distinguish true viral variants
from erroneous mutations, with the majority of methods
tailored to the 454 platform such as AmpliconNoise [29]
and ReadClean454 [30]. Other tools aimed at detect-
ing low frequency variants include Segminator II [31]which is specialised towards temporally sampled data,
V-Phaser which utilises information on the co-location of
variants on reads [32,33], Lo-Freq which utilises quality
scores to model base miscalls [34], and an approach which
incorporates re-sequencing with reads distribution and
strand bias [35]. However, these tools do not consider the
error effects of the RT or PCR processes; although Flux
Simulator [36] does consider these processes it is specia-
lised towards RNAseq datasets.
Here we focus on FMDV which has a genome of ~8.3 kb
and is a non-enveloped, positive-sense, single-stranded
RNA virus in the Aphthovirus genus of the family Picorna-
viridae. FMDV is the causative agent of the highly conta-
gious and economically serious foot-and-mouth disease
(FMD), a vesicular disease of cloven-hoofed animals, which
can spread extremely rapidly and has the potential to cause
enormous economic losses. In this study, we have created
a set of novel control samples in the laboratory that are all
derived from a DNA plasmid containing a full-length
FMDV cDNA with extremely limited diversity in the start-
ing population. One sample was ultra-deep sequenced on
the Illumina platform without any RT-PCR sample pro-
cessing, whilst the other samples were either PCR or RT-
PCR amplified prior to sequencing. This enabled the level
of error introduced by the RT and PCR processes to be in-
dividually assessed and also enabled minimum frequency
thresholds to be set for true viral variant identification.
We combined these experimental data sets with a genome
wide computational model of the sample processing and
NGS calling process to gain a detailed understanding of
the error rates and thresholds at each step. Furthermore,
we demonstrate how the model can also used to investi-
gate a specific site of interest in any NGS data set, by
utilising the site’s coverage, quality scores, and the fitted
RT-PCR error distributions, one can investigate if the
number of mutations observed are more than would be
expected from processing errors alone. Combined, these
data sets and the computational model provide an effect-
ive means of separating true viral mutations from those
erroneously introduced during sample processing and
sequencing.
Methods
Control sample and data preparation
Control sample preparation was performed in the high
containment laboratory of the Pirbright Institute. The
starting template used for all samples was an 11,278 bp
pT7S3 plasmid containing a full-length FMDV B64
strain O1Kaufbeuren cDNA ([37], kindly provided by
Veronica Fowler, Pirbright Institute). The DNA se-
quence of this plasmid clone had been determined previ-
ously by the Sanger method. This plasmid was clonally
amplified in E. coli to create the necessary quantity of
DNA for direct sequencing and as the starting template
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bacterial DNA polymerases (estimated to have an error
rate of between 10−9 and 10−11 errors per base pair cop-
ied [38]), the clonally amplified plasmid represents a
relatively clonal starting population with a extremely
limited diversity. Linearised pT7S3-O1K B64 plasmid
(concentration of 109 plasmid per μl) was generated using
the restriction enzyme HpaI which in turn was used to
generate four different control samples spanning three
areas of error introduction (Figure 2):
1) Sequence: A 7,856 bp DNA fragment containing
80% of the FMDV genome was cut from the
undiluted linearised pT7S3-O1K B64 plasmid using
restriction enzyme digestion with PstI and then gel
extracted. No RT or PCR was required to amplify
this clonal sample.
2) PCR-low: Undiluted and linearised pT7S3-O1K B64
plasmid was subjected to two independent PCR
amplifications, 19 cycles each, to generate 2
independent but overlapping PCR products -
PCR1 and PCR2 - which are 4065 bp and 4033
bp in length, respectively. The DNA polymerase
(DNApol) used in this PCR process was Platinum
Taq High Fidelity (Invitrogen).
3) PCR-high: Linearised pT7S3-O1K B64 plasmid was
diluted to 106 plasmid DNA copies per μl (so as to
result in the same amount of final DNA product as
PCR-low), and then subjected to two independent
PCR amplifications of 39 cycles each, to generate
PCR products PCR1 and PCR2. PCR efficiency wasFigure 2 Control sample processing and genome targets. (a) is a sche
that each one has undergone. The numbers in brackets represent the num
transcription denotes that there was a preceding transcription step. (b) is a
the control samples covers, and the regions that are directly comparable bmeasured with efficiency measured at 80% during
the initial stages of PCR (see Additional file 1). The
106 starting copy number and 39 cycles of PCR are
the optimised values used to process FMDV samples
for NGS sequencing determined from our previous
studies [18], where further details of the laboratory
protocol can be found.
4) RT-PCR: Linearised pT7S3-O1K B64 plasmid was
diluted 1000 fold to 106 plasmid DNA copies per μl,
was first transcribed from DNA to RNA using the
MEGAscript T7 kit (Ambion), and then reverse
transcribed using Superscript III (Invitrogen) to gen-
erate cDNA followed by amplification via 39 cycles
of PCR to generate PCR products PCR1 and PCR2,
as above.
The Sequence control sample covers a slightly different
portion of the plasmid genome than the remaining three
PCR amplified samples due to the different location of the
PstI restriction site to the previously optimised PCR primer
sites (Figure 2); restriction site selection was influenced by
biosecurity measures whereby no more than 80% of the
FMDV genome could be transported out of the high secur-
ity area for sequencing. To enable direct comparisons
between all the samples, we focus our analyses on the por-
tions of the FMDV genome that are shared between all of
the samples (Figure 2). The ends of the DNA fragments are
ignored due to large spikes in coverage at these positions,
due to sonication bias.
Control samples were sequenced at the Polyomics
Facility, University of Glasgow, on an Illumina Genomematic of the four different control samples and the processing
ber of PCR cycles used during PCR steps, the (2) label on reverse
schematic of the DNA plasmid used, the genomic regions each of
etween all controls and used for later analyses.
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ation and the resultant fragment distribution assessed on
an Agilent BioAnalyzer 2100 platform. After size selec-
tion of fragments of between 300 and 400 bp, a library
of purified genomic DNAs was prepared by ligating
adapters to the fragment ends to generate flow-cell-
suitable templates. A unique 6-nt sequence tag for mul-
tiplexing was added to each control sample followed by
PCR of 10 cycles using Phusion Oy (Finnzymes) DNA-
pol. The amplified and tagged DNA samples were then
pooled and attached to the flow cell by complementary
surface-bound primers, isothermal bridging amplifica-
tion formed DNA clusters for reversible terminator se-
quencing, yielding reads of 73 nucleotides.
Reads were processed using a previously developed
pipeline [17,18]; however, other tools such as bwa [39]
and bowtie [40] could be used as alternatives. Reads
were first trimmed from 73 nt to 70 nt due to the very
poor quality of the last 3 bases and then filtered, with
reads discarded if they had an average probability of
error per nt greater than 0.1%. The trimmed and filtered
reads were then aligned to the plasmid reference gen-
ome with a simple, custom-made scoring algorithm, pre-
viously described in [17,18]. We further trimmed the
first and last 6 nts of each aligned read, as they showed
a higher number of mismatches to the reference se-
quence due to insertions or deletions close to the edges
of the reads [17,18,20,41]. Information on the aligned
reads is then piled-up to give the reference base, cover-
age and the number of As, Cs, Gs and Ts at each gen-
ome position along with an average probability of a
sequencing error derived from the quality scores. The
fastq files from all four samples have been uploaded
to the EBI SRA repository (http://www.ebi.ac.uk/ena/)
with the accession numbers ERR776658, ERR776657,
ERR77656, and ERR776655 for the RT-PCR, PCR-
High, PCR-Low and Sequence controls respectively.
Computational model
The computational model operates at the population
level. Instead of modelling 109 or 106 individual genomes
(viral or plasmid) through the exponential PCR process,
which would be computationally intensive, we view the
population as an array or alignment of 106 initial ge-
nomes and operate on the numbers of As, Cs, Gs, and
Ts present at each genome position. This population
view is based on the assumption that the copying of
each individual base in each genome during PCR (or
RT) is independent and is therefore a single binomial
trial with a probability of success (a mutation) equal
to the DNA polymerase error rate. Therefore, with 106
genomes being duplicated in the first PCR cycle, each
individual genome position is independently copied
106 times with a mutation potentially introduced eachtime. An example of the alignment view and error accu-
mulation through PCR cycles is presented in Additional
file 1.
After simulation, the model gives a polymorphic/mis-
match frequency (number of non-reference bases/total
bases) for each genome position, which we present in
the form of a mutation spectrum. The spectrum is gen-
erated by grouping genome positions into discrete bins
based on their observed mismatch frequencies and then
plotting the proportion of nucleotide sites in each mis-
match bin (y-axis) against the mismatch frequency of
the bin (x-axis; e.g. Figure 3). This spectrum provides a
richer view of the diversity within a viral population, and
enables easy comparison between populations. The mu-
tation spectrum outputted from the model is then com-
pared to the mutation spectrum from the corresponding
experimental data set to give a sum of squares score (S)
representing how well the model recreates the experi-
mental data:
S ¼
Xb
1
Ei−Mið Þ2
Where b is the number of polymorphic bins, and Ei
and Mi are the number of nucleotide sites (represented
as a proportion of all sites) in the ith polymorphic bin,
for the experimental (E) and model (M) mutation
spectrums, respectively. For model fitting and parameter
estimation, we use a Sequential Monte Carlo (SMC)
algorithm [42-45], a form of Approximate Bayesian
Computation (ABC). We use the SMC algorithm pro-
posed by [43], further details of which are presented in
the Additional file 1, but briefly a parameter (or particle)
θ is sampled from a prior distribution π(θ) and propa-
gated through a sequence of intermediate distributions
π(θ|d(x0, x
*) ≤ εi) until it represents a sample from the
target distribution π(θ|d(x0, x
*) ≤ εT). d is the distance
between the model simulated dataset (x*) and the labora-
tory data set (x0) calculated by the sum of squares score
above. The tolerances εi are minimum distance scores
and are chosen such that εi >… > εT ≥ 0, thus the distri-
butions gradually evolve towards the target posterior.
For the model fitting, we used uniform prior distribu-
tions and a dynamic tolerance schedule that progres-
sively decreases the tolerance at each step. The SMC
process essentially fits the model parameters to the given
data set, and thus provides estimates of the error rates
of the enzymes used during RT and PCR, as well as the
underlying distributions involved.
The model is composed of a number of sample
processing steps enabling various combinations to be
selected for a simulation (the parameters at each step can be
either manually set at the simulation start or dynamically fit
by the model to the provided NGS data set):
Figure 3 Experimental data mutation spectra. The mutation spectrum of each of the experimental samples: Seq (blue), PCR-Low (red), PCR-High
(green) and RT-PCR (purple) along with a real FMDV sample (black) from an infected cow (A5-7DPFC-PB in [18]). Each genome position considered is
placed into a discrete bin based on its mismatch (to the reference) frequency. The x-axis represents the mismatch frequency of the bin whilst the y-axis
represents the number of genome positions that are in that bin. Both axes are presented on a log10 scale.
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diversity of the viral population. This can be set to
Clonal (no diversity), Fixed (all genome positions
have the same initial mismatch frequency, or
Sampled where the initial mismatch frequency
of every genome position is drawn from a Beta
distribution (αS, βS) where αS, βS are the two
shape parameters of a Beta distribution; αS, βS
can either be defined or added to the parameters
to be estimated. For this study, we use the Clonal
(no diversity) setting.
2) Determine RT enzyme error profile: Assuming
the RT enzyme is more likely to make errors
(mutations) at some genome positions than others
(in a sequence specific manner) the RT enzyme
error rate for each genome position is randomly
selected from a Beta distribution (αR, βR).
Alternatively, one can simply use a single RT
enzyme error rate for all genome positions.
3) Transcription and Reverse Transcription: As our
starting clonal sample is DNA, we first transcribe
our DNA to RNA so that it can be reverse
transcribed back to cDNA, enabling us to evaluate
errors that impact upon the RNA template. We
therefore represent this process as two distinct
steps but where transcription uses the same
parameters as reverse transcription, as we are unable
to disentangle these two processes from each other
using the data sets available. Transcription and
reverse transcription are linear copying processes,
with the original template removed after completion.
Each genome position is considered in turn, where
the population at each of the 4 bases (A, C, G, and
T) at that position is also considered in turn. Errorintroduction is modelled by a binomial distribution
(nij, pRi), where pRi is the RT enzyme error rate at
genome position i and nij is the number of the jth
base currently at genome position i. A random draw
from this distribution gives the number of errors
made, each error is randomly assigned to one of
the other 3 bases at that genome position whose
population increases by one, whilst that of the
transcribed base decreases by one.
4) Determine DNApol error profile: Assuming the
DNApol enzyme is more likely to make mutations at
some positions than others, the DNApol error rate
for each genome position is also randomly selected
from a Beta distribution (αD, βD). Alternatively, one
can simply set the DNApol error rate to be the same
for all genome positions.
5) Sample preparation PCR: Each genome position is
considered in turn, where the population at each of
the 4 bases (A, C, G, and T) at that position is also
considered in turn. First, if PCR efficiency is not
100% the number of bases to be copied is
determined from a binomial distribution (nij, pC),
where pC is the PCR efficiency for PCR cycle c and
nij is the number of base j at genome position i; the
population of base j is then increased by the number
of bases to be copied. Second, the number of
mutations that were made during copying is
determined from another binomial distribution
(nij, pMi) where pMi is the DNApol error rate at
genome position i and nij is the number of the jth
base copied at genome position i (determined from
first step); Poisson and then normal approximations
to the binomial are used when the population of nij
is high (>100 and >109, respectively). Third, the
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number of mutations to be made, and for each
mutation the resulting mutated base is randomly
selected to be one of the 3 other bases whose
population increases by 1.
6) Sonication: The 5% sampling bottleneck caused by
sonication is represented by a hyper-geometric
distribution (which describes the probability of
k successes in n draws). Here we use the Poisson
approximation of the hyper-geometric for speed, and
the corresponding normal approximation when the
base population (n) is large. A Poisson distribution
(λij) is used if the base population is <10
9 where λij is
the mean and equal to [5% × population at genome
position i base j]; for base populations >109 we use
the normal approximation of the hyper-geometric.
7) Illumina Library PCR: The 10 cycles of PCR
performed during the Illumina library preparation
proceeds in the same manner to the sample
preparation PCR above, except that the DNApol
error rate is fixed for each genome position to the
published error rate of Phusion Oy (Finnzymes;
1 in 2,272,727).
8) Illumina Sampling: The reads obtained from an
Illumina sequencing run represent a small sample
of the amplified Illumina library. To represent this
bottleneck, a sample of bases is randomly selected
stochastically from the population present at each
genome position, with the number of bases to be
sampled given by the read coverage at that genome
position from the corresponding experimental data set.
9) Illumina Error: Every base in every read is assigned a
quality score (Q) by the Illumina machine, which
can be converted into a probability of error (p) with
the formula p = 10-Q/10. For each genome position, a
mean probability of error can then be calculated
from all the quality score p values aligned at that
position. The number of Illumina errors at each
position is then modelled by randomly drawing from
a binomial distribution (ni, pEi) where pEi and ni are
the average probability of a sequencing error and the
coverage at genome position i, respectively.
Results
Data analysis
After read filtering and alignment, coverage was high
and similar in all four samples with an average coverage
of 34,000 in the Seq control sample (Figure 4). Although
coverage is variable across the genome, this variability is re-
producible as all four samples display the same peaks and
troughs in coverage at the same positions suggesting cover-
age is related to the underlying genome sequence. This
variation correlates well with GC content (Additional file 1)
and has previously been reported to influence coverage dueto amplification bias during the Illumina library preparation
PCR [46]. The very high peaks in coverage observed in
Figure 4 occur at the end of the DNA fragments (both
excised and PCR amplified) and are over-represented in the
data set, presumably as a result of sonication bias at the
end of DNA fragments.
Figure 3 displays the mutation spectra of the four ex-
perimental samples and represents a novel data set that
measures the amount of error introduced during each
stage of processing an RNA viral sample for sequencing,
with the mutation spectrum shifting progressively to-
wards higher error frequencies the more processing the
viral sample undergoes. For the Seq control sample, the
only source of error is from the Illumina machine and
this error is still clearly observable despite read and
alignment filtering; error from the Illumina library PCR
step is predicted to be negligible due to the high fidelity
of the DNApol used (see Additional file 1). The addition
of PCR to the sample preparation shifts the mutation
spectrum substantially to higher frequencies, and the
addition of RT shifts the spectrum further still. The me-
dian mismatch frequencies of each spectra are presented
in Table 1, along with the frequency at which 75%, 95%
and 100% of genome positions are below. These fre-
quencies can be used to set minimum thresholds above
which one can be confident that observed mutations are
real. For example, the maximum mismatch frequency
observed in the full RT-PCR sample is 0.66%, whilst 95%
of genome positions are below a frequency of 0.14%.
The mutation spectrum from a real FMDV sample ob-
tained from a foot lesion of an infected cow is also in-
cluded in Figure 4, this sample underwent the same
processing as the RT-PCR sample (minus the initial
DNA to RNA transcription step). The spectrum of the
real FMDV sample is similar to the clonal RT-PCR sam-
ple at low frequencies which represents the error intro-
duced from sample processing and base calling, but it
clearly diverges away from the clonal samples at a fre-
quency of 0.5% bin onwards which therefore represent
real biological variants in the viral population. There is
undoubtedly real low frequency viral variation below
0.5% in the sample due to nature of viral replication,
however this is practically indistinguishable from process
error at this level.
Table 1 shows that the maximum observed mismatch
frequency in the RT-PCR sample was 0.66%; in the mu-
tation spectrum this genome position is placed in the
bin that has a midpoint of 0.5% (Figure 4). We can be
highly confident that any mutation observed above this
frequency is true, for samples processed with this proto-
col. However, there are likely to be a number of true
viral variants present below this threshold. Figure 4
shows that the real FMDV sample begins to deviate from
the RT-PCR sample at the 0.157% threshold, with more
Figure 4 Genome Coverage. The read coverage for each of the samples across the 11,278 bp plasmid genome: Seq (blue), PCR-Low (red),
PCR-High (green) and RT-PCR (purple). The peaks correspond to the ends of DNA fragments, which are over-represented in the data set, presumably due
to sonication bias; as can be seen the Seq sample operates on a slightly different section of the genome (Figure 2) but with substantial overlap with the
PCR amplified samples. The two regions of the genome that are used for direct comparison between all samples are highlighted with dashed black boxes,
which avoid the regions with large and potentially biased coverage spikes at the ends of DNA fragments and primer regions. The Seq control (blue) suffers
a drop in coverage at around position 2,500 due to a large poly C tract that is found in all FMDV genomes, and which is problematic for both PCR
and sequencing.
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point on. A total of 226 variants are observed above this
threshold in the RT-PCR control sample, whilst 516
variants are observed in the real FMDV sample, 290 of
which are therefore likely to be true. A threshold of
0.66% would correctly identify all the errors (100% speci-
ficity), but would only identify 32 of the 290 likely
variants in the real FMDV sample as true. Lowering
the threshold by half to 0.3% results in a doubling of the
number of likely true variants identified to 75 at a
relatively small cost with specificity only dropping to
99.86%. Whilst at a threshold of 0.15%, specificity drops
to 96% with 226 errors falsely identified as true, but all
290 are the likely true variants also identified. It is im-
portant to note that a threshold will be dictated by the
actual sample processing used and must also be taken in
context. The fidelity of the enzymes used and the num-
ber of the PCR cycles will highly influence threshold set-
ting, whilst the coverage of a genome position and theTable 1 Variant frequency thresholds
25% 50% 75% 95% 100%
Seq 0.0119% 0.0183% 0.0268% 0.0466% 0.276%
PCR-Low 0.0261% 0.0371% 0.0518% 0.0793% 0.4074%
PCR-High 0.0323% 0.0457% 0.0623% 0.1004% 0.3755%
RT-PCR 0.0368% 0.0526% 0.0793% 0.1403% 0.6571%
Real 0.0309% 0.0510% 0.0916% 0.2113% 100%
This table contains the 25th, median 50th, 75th, 95th and the maximum
100th percentiles of genome position mismatch frequencies in each of
the four samples.quality of it’s aligned reads will influence a threshold in a
site specific manner.
Next we characterised all the base substitutions that
occurred in each of the clonal samples. In the Seq con-
trol sample, by far the most frequent base miscall was G
to T (a G miscalled as a T) which represented approxi-
mately 23% of all Illumina base miscalls, followed by T
to C, C to T, G to A and A to G which varied between
approximately 12% and 15% (Additional file 1). Over
40% of all Illumina errors occurred at G positions, even
though there were less G positions in the genome se-
quence considered than A or C positions; the remaining
60% of errors were distributed equally between the A, C
and T positions. This suggests that the Illumina machine
is more prone to error at G positions and could reflect
the known issues with GGC and GGX motifs discussed
previously. For the PCR samples, the most common base
substitutions are those representing transitions between
the purines (A to G and G to A) and pyrimidines (T to
C and C to T), all of which are dominant within the
dataset; although the A to G and T to C transitions are
more abundant. Although substantially lower than these
transitions, the G to T is by far the highest transversion,
highlighting the contribution of the above Illumina error
into the overall mutation spectrum. The RT sample
shows the same characteristics as the PCR sample.
Overall, the mutation spectra suggest that Illumina
error is clearly observable and should therefore be con-
sidered when examining viral populations at ultra-deep
coverage. The main bulk of the error appears to come
from the PCR process rather than the RT step, but RT
Orton et al. BMC Genomics  (2015) 16:229 Page 9 of 15does substantially affect the high frequency end of the
spectrum. Although RT enzymes have higher error rates
than their PCR counterparts, PCR utilises numerous
amplification cycles and as errors are cumulative the
amount of PCR error in the sample increases with each
cycle.
Computational model
We next developed a computational model of the sam-
ple preparation and sequencing process to parameterise
each process and the errors that are introduced. In the
model, the Seq control sample starts with an initial
population containing no diversity, this is then sonicated
(5% sampling), has library prep PCR amplification of
10 cycles, and is sampled at each position by the corre-
sponding coverage in the real data set. Illumina base
miscalls are represented via random draws from a bino-
mial distribution based on the coverage and probability
of sequencing error (derived from quality scores) at each
genome position. This relatively simple approach to
address Illumina error has been used successfully on
FMDV [17,18] and other systems [47]. Figure 5A shows
that there is ample agreement between the simulatedFigure 5 Model simulated data mutation spectrums. The mutation spe
experimental data set: (A) Seq experimental (solid blue) and simulated (das
fixed DNApol error (dashed green), and simulated distributed DNApol erro
distributed RT error (dashed red).and experimental data sets for the Seq control sample
but the model slightly overestimates the amount of error
introduced via Illumina miscalls. One possible explan-
ation is that the probability of error associated with each
quality score should in fact be lower (better quality) than
the published value. This was also suggested in [9], who
observed significantly lower mismatch rates than pre-
dicted from Illumina, quality scores when using overlap-
ping paired-ends.
For the PCR-high model, there is poor agreement be-
tween the simulated and experimental data sets when
one assumes that the DNApol error rate is the same for
all genome positions (Figure 5B). When genome posi-
tions have the same mutation rate, there is not enough
diversity in the predicted mutation spectrum. However,
when one assumes that the DNApol enzyme is more
likely to make mutations at some positions than others,
through a Beta distribution, there is good agreement to
the experimental data (Figure 5B). This could be due to
the sequence composition of the surrounding bases
influencing the likelihood of the DNApol making an
error at certain positions. The model predicts that the
median error rate of the DNApol used (Platinum Taqctra of simulated data sets compared to its corresponding
hed red) and (B) PCR-High experimental (solid blue), simulated
r (dashed red); (C) RT-PCR experimental (solid blue) and simulated
Orton et al. BMC Genomics  (2015) 16:229 Page 10 of 15High Fidelity; Invitrogen) to be 2.20 × 10−5 substitutions
per nt copied from the fitted Beta distribution (2.01,
76254), which is only slightly higher than the manufac-
turers published error rate of 1.8 × 10−5 (6 times the
error rate of standard taq; Invitrogen). This Beta distri-
bution results in variation between genome positions,
with some positions slightly more or less prone to error
during each PCR cycle than others (Figure 6), which will
be magnified the more PCR cycles are used.
Similarly, for the RT-PCR model, there is again good
agreement between the simulated and experimental data
sets when one assumes the RT enzyme is more likely to
make mutations at some positions than others (Figure 5C).
The model predicts a highly skewed beta distribution (0.19,
3074 to represent the error rate of the RT enzyme used
(Superscript III – Invitrogen), with a low median error rate
of 5.31 × 10−6 but with a mean an order of magnitude
higher at 6.13 × 10−5 substitutions per nt copied (Figure 6),
which is within the range of published error rates for
Superscript III (6.66 × 10−5 to 3.12 × 10−5; Invitrogen and
[48]) which again varies depending on the assay used. The
95th percentile of this distribution has an error rate of 3.2 ×
10−4 suggesting some genome positions are highly prone to
error during the reverse transcriptase process. This could
be due to sequence specific effects or perhaps the 2D/3D
structure of the RNA influencing where the reverse tran-
scriptase makes an error.
Through model fitting, we now have a good under-
standing of each of the sample processing stages along
with their enzyme error rates and underlying distribu-
tions involved. As sequencing is always performed with
DNA, reverse transcription of RNA viruses must always
be performed. However, future technological advancements
could make PCR redundant (via minimisation of starting
DNA levels) or make future sequencing machines error-
proof. Therefore, the model was used to examine the
impact of such developments. Figure 7 shows that when
the sample preparation PCR is removed, the peak of the
mutation spectrum shifts substantially to lower frequencies.
However, the high frequency end of the spectrum is still
visible demonstrating that the RT process alone canFigure 6 Beta distributions representing enzyme error rates. The mod
polymerase (blue line) and Reverse Transcriptase (red line) enzymes. 100,00
rates are logged (base 10) and the x-axis is truncated at −11 (the RT distrib
focus on the differences between the two distributions.generate observable high frequency mutations due to the
skewed nature of its error distribution. When Illumina
error is removed as well, the mutation spectrum changes
drastically, with most genome positions (58%) having no
observable error in the NGS reads. However, high fre-
quency mutations up to the 0.5% threshold are again still
observable again due to highly skewed error distribution of
the RT process. Overall, this suggests that although PCR
and Illumina machine error do contribute substantially to
the mutation spectrum, removing them does not substan-
tially affect the high frequency tail end of the spectrum or
the minimum frequency thresholds. However, an error-
proof sequencer capable of sequencing tiny amounts of
DNA without PCR amplification would obviously be a
major technological advancement. Although some sites
would still have “high” frequency variants (due to the RT
process), the majority of the genome will have no observ-
able error, whilst only 5% of sites would have an observable
error above 0.07%. This demonstrates that it is important
to consider the overall error distribution of processes such
as RT and PCR when selecting an appropriate frequency
threshold and deciding upon the amount of error one is
willing to tolerate. We investigated the effect of coverage
and quality scores on the frequency threshold (Additional
file 1), and found the 0.5% threshold to be stable at cover-
age’s of 10,000 and above, but the threshold does increase
below this coverage. In addition, lowering the quality of the
reads increases the threshold across all coverage levels,
again highlighting that a threshold should be considered in
context with all available information taken into account.
A secondary use of the model is to investigate whether
the number of observed mutations at a given genome
position of interest in a real viral data set is greater than
would be expected from processing errors alone. The
model is first provided with the genome position’s cover-
age and quality scores, along with the biological sample
processing information. The model then utilises the pre-
viously determined RT and PCR enzyme error distribu-
tions to simulate the number of mutations that would be
observed from processing errors alone at this position.
The simulation is essentially replicated 4,500 times asel derived beta distributions representing the error rates for the DNA
0 samples were randomly drawn from each Beta distribution. All error
ution has a long low density tail stretching to −30) to aid viewing and
Figure 7 Predicted mutation spectrums with higher fidelity polymerase and the true diversity of a real sample. The predicted mutation
spectrum of the full RT-PCR sample (blue), RT with no sample preparation PCR (red), and RT with no sample preparation PCR or Illumina
error (green).
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given coverage and quality scores, but each position
receives a random draw from the RT/PCR error distri-
butions. The resulting histogram then displays the range
of error mismatches that could be observed at this pos-
ition given the variations due to sampling bottlenecks,
stochasticity, and the enzyme error rates (Figure 8). ThisFigure 8 Simulated number of mismatches from sequence and proce
simulated 4,500 replicates, with each replicate having the same coverage (2
a random draw from the enzyme error distributions. The simulated numbe
bars) that can then be compared to the real number of mismatches observ
in the real biological data set, it is unlikely that any of these are real given
(grey dotted bar) it is much more likely that there is real biological variatiohistogram can then simply be compared to observed
number of mutations to determine how likely it is that
they are real.
Figure 8 is an example of setting a frequency threshold
in the context of a genome position of interest. In such
a case, one already knows the coverage and quality
scores, both of which can greatly affect a frequencyss error alone at a specified site. For a given site, the model
5,000) and average sequence error (0.000223) of the site, but receiving
r of mismatches for all replicates is presented as a histogram (black
ed at the specified site. If one had observed 15 mismatches (grey bar)
the simulated distribution. However, if one observed 30 mismatches
n at this site.
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coverage of 100 a single erroneous mutation would re-
sult in a frequency of 1% but is unlikely to be trusted),
whilst a site with poor quality could similarly lead to a
high error frequency from machine miscalls alone.
Therefore, the model can be used to investigate the
possible affect the RT and PCR processes are having at a
specific site given what is already know from the se-
quence data. We envisage that the model would be used
in this case for a select number of genome positions,
such as though at the higher scale of the mutation
spectrum, or specific sites of interest such as those that
convey drug resistance, pathogenicity or become fixed later
on in a transmission chain, due to the computational cost
of running the model across the whole genome.
Discussion
NGS technology provides the means to go beyond con-
sensus sequences and investigate the population struc-
ture of viral samples. The introduction of erroneous
mutations during the sample preparation process and
miscalls during sequencing confounds the identification
of true low frequency viral variants. Identifying such
variants is important when tracing the source and devel-
opment of specific mutations of interest, or when com-
paring the total diversity within viral populations, such
as those before and after a bottleneck. In this study, we
generated and analysed a collection of novel NGS data
sets that reveal the amount of error introduced during
each viral sample processing step and used them to set a
minimum frequency threshold of ~0.5% to separate real
mutations from process error. However, this threshold
could be lowered at the cost of specificity, and will
naturally vary depending on the specifics of the sample
processing steps used such as enzyme fidelity and
number of PCR cycles. We complemented this with a
genome-scale model to gain a deeper understanding of
each processing step.
The data and model show that despite high quality
read filtering, Illumina error is still observable, although
typically at relatively low frequencies. The introduction
of PCR resulted in a substantial increase in the observ-
able error to higher mismatch frequencies. However,
using the highest fidelity DNApol enzymes and minimis-
ing the number of PCR cycles will logically reduce the
amount of PCR error introduced. The model predicted
the mean error rate of the DNApol used (Platinum Taq
High Fidelity; Invitrogen) to be 2.64 × 10−5 substitutions
per nt copied, which is only slightly higher than the
manufacturers published error rate of 1.8 × 10−5 (6
times the error rate of standard taq; Invitrogen); a fur-
ther study using novel BEAMing technology estimated a
lower bound error rate of 1.4 × 10−5 [49]. However, the
measured error rate is extremely dependent on the assayused, with estimates for Taq itself range from 1.1 × 10−4
[50] to between 2.3 × 10−5 [49] and 2.7 × 10−5 [51]. In
this report, we have used a novel approach using NGS
reads to estimate the error rate, and propose that the
error rate is in fact best represented with a distribution
rather than a single value. The model predicted a mean
error rate of the RT enzyme used (Superscript III;
Invitrogen) to be 6.13 × 10−5 substitutions per nt copied,
which is within the range of published error rates for
Superscript III (6.66 × 10−5 to 3.12 × 10−5, Invitrogen
and [48]) which again varies depending on the assay
used. Our RT-PCR sample was first transcribed into
RNA using T7 polymerase (Ambion) before reverse
transcription back into DNA. Therefore, the RT error
rate estimated by the model is applied to both the tran-
scription and reverse transcription steps as these two
steps cannot be fitted separately with the available data.
If the transcription step is less error prone, then the RT
step will in fact have a higher error rate than we have re-
ported here to compensate, and vice versa.
The model predicts that not all genome positions are
equal and that some sites are much more prone to PCR
error than others. This novel model prediction could be
due to the sequence composition of surrounding bases
influencing the likelihood of DNApol making an error,
which has previously been reported for human polymer-
ase v [52]. The model also makes a similar prediction for
the RT process, which resulted in a highly skewed Beta
distribution with some genome positions highly suscep-
tible to error. Interestingly, this does not appear to be
specific to the RT-PCR enzymes (Platinum Taq High
Fidelity and Superscript III) or viral sequence (FMDV)
that we used in this study. Similar findings have been
reported with Hepatitis C virus [53], using different RT-
PCR enzymes combined with a consensus sequencing
strategy of numerous molecular clones. They reported
that RT-PCR errors were not evenly distributed, but were
concentrated in specific hotspot regions, one of which coin-
cided with a known region of hyper-variability in the viral
genome. This suggests that any specific sequence context
or secondary structure that negatively impacts on the RT-
PCR enzymes may also affect the viral RNA polymerase it-
self. Therefore, hyper-variable regions in viral genomes may
be, in part, the result of natural polymerase mutational hot-
spots. Overall, identification of the sequence and structural
signatures of mutational hotspot regions, and a comparison
of these between different viruses would make an interest-
ing study and could lead to novel insights into what drives
the mutational dynamics of viruses.
From the data itself we identified a minimum frequency
of ~0.5% above which one can be reasonably confident that
an observed mutation is real. However, a minimum mis-
match frequency threshold should be interpreted with
some caution and must always be considered in context, as
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age at a genome position. For example, 1 observed mis-
match at a genome position with a coverage of 100 leads to
a mismatch frequency of 1% which would appear relatively
high. However, a single mutation is not reliable given the
error prone nature of the processes, and a coverage of 100
would be considered low compared to the average of
34,000 observed in our Seq control data set, suggesting an
underlying problem with that genome position that has re-
sulted in limited coverage. Additional filters should there-
fore be applied when validating the mismatches at a
particular genome position, such as minimum coverage
cut-offs, and validation against the number of mismatches
expected given the sample processing procedure.
To address this, our model can also be used to investi-
gate if the mutations observed at a given genome pos-
ition are real, by simulating the number of mutations
that would be expected from sequencing and sample
processing error alone, and comparing this distribution
to the observed number. This could be applied to any
viral Illumnia data set, and adapted to represent alterna-
tive RT-PCR enzymes if estimates of their error rates are
known; alternatively, one could simply run the model
multiple times scanning through a range of enzyme
error rates. Although we used 39 cycles of PCR in our
optimised protocol, alternate virus/system protocols may
well utilise fewer cycles. As shown in Figure 4, when the
number of PCR cycles is halved, the mutation spectrum
shifts substantially to lower error frequencies. Therefore,
one should logically limit the number of PCR cycles
used if possible as PCR errors accumulate with each
cycle. Alternatively, there are high-fidelity polymerases
available that have published error rates orders of mag-
nitude above the Platinum Taq polymerase used in our
protocol, which will also greatly reduce the observed er-
rors. However, in both cases the RT step remains which
alone can still result in erroneous high frequency vari-
ants, although only at relatively few genome positions.
In addition, as Illumina machines share the same se-
quence by synthesis chemistry, and as we utilise the
quality scores outputted by the sequencer itself, our re-
sults are applicable to more recent machines.
Recent techniques have been developed [54,55] that
utilise the fragmentation followed by circularisation of
viral RNA. Each small RNA circle is then reverse tran-
scribed multiple times to create a single cDNA strand
with multiple copies of the original RNA sequence. The
cDNA can then be directly sequenced (after library
adapter ligation) and as each read will contain multiple
copies (typically three) of the same viral RNA sequence,
reverse transcriptase errors and sequencer base miscalls
can be readily identified; a similar strategy to that of uti-
lising overlapping read pairs [9]. These approaches are
very promising, however, they are currently limited toin-vitro samples due to the substantially large amount of
initial viral RNA required, as they do not utilise PCR at
any step. Therefore, our strategy still provides a valuable
means for identifying and quantifying errors introduced
during the processing of biological samples, such as field
isolated during an epidemic, which typically have to
amplified to achieve the required amount of RNA as
standard. Furthermore, our results that reverse tran-
scriptase is highly prone to error at some sites, may have
implications for such circular re-sequencing techniques.
An alternative approach to error handling is the incorp-
oration of unique barcodes into sample DNA which have
been successfully applied to viral population and fitness
analyses [56,57].
Our work here has been focussed on the Illumina plat-
form, but application of the same experimental tech-
niques would be useful to assess and compare the error
profiles, in terms of viral populations, of different plat-
forms. It would also be possible to apply the models to
other platforms, although this would likely involve sub-
stantial more work. Although a large proportion of the
models, such as the RT-PCR component, could be dir-
ectly applied to other sequencing platforms, the models
would then need to be extended to represent each plat-
form’s specific sample preparation protocol and sequen-
cing error profile.
Conclusions
We have created a novel set of laboratory control sam-
ples that enabled the level of error introduced by the
RT and PCR processes to be assessed and minimum
frequency thresholds to be set for true viral variant iden-
tification. We combined this with a genome-scale com-
putational model of the sample processing and NGS
calling process to gain a detailed understanding of the
errors at each step, which predicted that RT and PCR
errors are more likely to occur at some genomic sites
than others. The model can also be used to investigate
whether the number of observed mutations at a given
site of interest is greater than would be expected from
processing errors alone in any NGS data set. These data
sets and models provide an effective means of separating
true viral mutations from those erroneously introduced
during sample processing and sequencing. Furthermore,
the data sets themselves provide an ideal test set for the
evaluation of viral variant calling tools to assess their
ability to distinguish real viral variants from RT-PCR
and sequencer errors.
Availability of supporting data
The raw FASTQ files from all four control samples will
be deposited and made publicly available from the Se-
quence Read Archive (SRA) at the European Nucleotide
Archive (ENA).
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